REFERENCES
- Osol A. Remington's Pharmaceutical Sciences. 15th ed., Mack Publishing, Easton, PA 1975; 830
- Martindale. The Extra Pharmacopoeia. 31st ed., Pharmaceutical Press, London 1996; 1422
- Broggini M., Benvenuti C., Botta V., Fossati A., Valenti M. Bioavailability of intranasal neostigmine comparison with intravenous route. Meth. Finding Exp. Clin. Pharmacol. 1991; 13(3)193–198
- Porst H., Kny L. The structure of degradation products of neostigmine bromide. Pharmazie 1985; 40(5)325–328
- Porst H., Kny L. The kinetics of neostigmine degradation in aqueous solution. Pharmazie 1985; 40(10)713–717
- Kulikov S. I., Bokovikova T. N. Spectrophotometric determination of neostigmine methylsulfatein drugs. Pharmazie 1985; 36: 43–45
- Ruyter M. G. Reverse phase ion pair L.C. determination of pyridostigmine, neostigmine, and endrophonium in biological fluid. J. Chromatogr. Biomed. Appl. 1980; 183: 193–201